In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

In a short time, single-cell platforms have become the norm in many fields of research,
including multiple myeloma (MM). In fact, the large amount of cellular heterogeneity in MM …

Background Multiple myeloma (MM) is a heterogeneous disease with different patterns of
clonal evolution and a complex tumor microenvironment, representing a challenge for …

The transcription factor, forkhead box M1 (FOXM1), has been implicated in the natural
history and outcome of newly diagnosed high-risk myeloma (HRMM) and relapsed/refractory …

Intratumor heterogeneity as a clinical challenge becomes most evident after several
treatment lines, when multidrug-resistant subclones accumulate. To address this challenge …

Abstract ABC portal (http://abc. sklehabc. com) is a database and web portal containing 198
single-cell transcriptomic datasets of development, differentiation and disorder of …

Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively
estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole …

Simple Summary Patients with lung cancer benefit from more effective treatments, such as
targeted therapies, and the overall survival has increased in the past decade. However, the …

Triple negative breast cancer (TNBC) remains the worst molecular subtype due to high
heterogeneity and lack of effective therapeutic targets. Here we investigated the tumor and …

Introduction Adrenocortical carcinoma (ACC) is a rare aggressive cancer with low overall
survival. Adjuvant mitotane improves survival but is limited by poor response rates and …